Strong Growth Masks Near-Term Regulatory Risks

Delivered Q2 QoQ revenue +11.8% — transcript match

OPM 26.4% in Q2 vs 22.7% prior quarter = 370 bps expansion (aligns with Q2 data)

Delivered Q2 QoQ PAT -4.1% (₹71.7 Cr vs ₹74.8 Cr Q1 implied), treasury line fell 82%

Delivered Q2 YoY: revenue +21.6%, PAT +33.9%; H1 PAT +39.1%

Specific claim on distributor onboarding supported by narrative of regulatory tailwind (MF regs April 2026)

MF PMS license application underway, launch expected April 1, 2027. Margin potential 80–90 bps (regulation allows charging 1% fee). Positions Prudent to capture HNI directly-managed AUM, no prior guidance on this.

Proposed IDA/IDE regime will reduce insurance profit contribution from current ~12% to uncertain level; agents earn 10% vs IDE 5% on renewals. Prior guidance did not flag this sector risk; management now acknowledges potential for lower commission payouts post-April 2026.

MF regulatory changes (April 2026) drove 3,541 new distributor additions in H1 FY27, ~30% above H1 FY26. Prior guidance mentioned '~30 branch additions' but did not quantify distributor network pace; now clear this is a major execution lever.

Claimed market share gains despite fintech/bank/distributor competition. Supported by SIP penetration rise (3.49% → 3.73%) and fresh sales outperformance, but no change to prior market-position guidance.

Insurance ~12% of profit; regulatory framework still evolving. Precedent: distribution saw entry-load cut, TER cut, industry adapted with volume. Won't all disappear overnight; will adjust gradually.

Don't have data readily available on POSP concentration. Renewal structure varies; 60-month persistency in health ~85–86%. Can't specify renewal impact without regulatory clarity.

Gaining market share QoQ. SIPs heavy on small/mid-cap; SIP penetration up 3.49% → 3.73%. Distributor loyalty, systems, team execution winning.

IDEs have infrastructure/tech/claim costs, margins higher than agents. Regulators seem receptive to our infrastructure model. Currently 88–89 bps very stable. Exact comfortable level = wait for final regulation.

PMS-MF launch April 1, 2027. Can charge 1% fee as manager, ~80–90 bps net. >90% overlap MFD/POSP at family level, not exclusive.

Basis of Q2 revenue. No change to prior guidance; regulatory environment supports margin floor.

Q2 OPM 26.4% vs 22.7% prior; expansion came from revenue growth + cost leverage. Insurance margin pressure from regulation unquantified.

Current contribution ~12% of profit. Renewal commission structure TBD by regulator. Commission payout 56.2% of revenue reaffirmed for overall business.

Proposed regulation will shift insurance distribution from POSP (5% IDE commission) to IDA (10% agent) model. Management estimates current insurance contribution ~12% of profit. Margin impact uncertain pending final rules; potential headwind mid-to-late FY27.

Sharp market correction in October 2026. Investor sentiment negative on returns, redemption activity rising. SIP inflows providing cushion but growth slowing in weak environment.

Analyst asked for POSP concentration (top 50 vs total). Management declined to share data ('don't have readily available'). Insurance business concentration among handful of partners unquantified.

PMS-MF license expected April 2027; regulatory approval not yet confirmed. Launch timing and client acquisition pace uncertain. Revenue ramp slower than hoped if adoption lags.

Ranked 4th in retail AUM but 5th in net sales. Fintech platforms, large banks, and national distributors gaining. Distributor loyalty unproven in weak market.